Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

Model scores of the 29,894 trials active now.

Model score 28% for any early termination, 11% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-11-24. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: equalbreast cancergreater thanchemotherapyradiation
  Phrases that lowered it: aminotransferasepatients whoulnrelevantclinical
• Sponsor's past termination rate: 27.1% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports with a death: 17.8% (lowers risk) · Drug's FDA history
• Minimum age: 19 (lowers risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 84.4% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 21 (lowers risk) · Sponsor's track record
• Maximum age: not given (raises risk) · Who can join
• Drug's FAERS reports before start: 122068 (lowers risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design
• Drugs with FDA adverse-event history: 5 (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 28036 (lowers risk) · Drug's FDA history
• Sponsor's past trials: 70 (raises risk) · Sponsor's track record
• Number of arms: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery NCT02654119 · started 2015 · scored riskier than 94% of active trials completed
• Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Who Have Undergone Surgery NCT01106898 · started 2010 · scored riskier than 96% of active trials completed
• Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer NCT00629499 · started 2008 · scored riskier than 79% of active trials completed
• Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer NCT00821886 · started 2009 · scored riskier than 90% of active trials completed
• Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer NCT01498588 · started 2011 · scored riskier than 99% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.